About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

SUBSCRIBE TO LASER FOCUS WORLD MAGAZINE

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

SUBSCRIBE TO LASER FOCUS WORLD NEWSLETTERS

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

SUBMISSION GUIDELINES

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Professor Andrea M. Armani, University of Southern California
Ruti Ben-Shlomi, Ph.D., LightSolver
James Butler, Ph.D., Hamamatsu
Natalie Fardian-Melamed, Ph.D., Columbia University
Justin Sigley, Ph.D., AmeriCOM
Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
Professor Stephen Sweeney, University of Glasgow
Mohan Wang, Ph.D., University of Oxford
Professor Xuchen Wang, Harbin Engineering University
Professor Stefan Witte, Delft University of Technology

Indicators

Markets:

News

Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?

By: MarketBeat

January 09, 2023 at 14:38 PM EST

Apexigen Stock Soars After Analyst Rating, is it Time to Buy?

Apexigen Inc. (NASDAQ: APGN) stock hit a limit up, limit down (LULD) pause early in the trading session on January 9. The catalyst is a bullish analyst rating from E.F. Hutton Acquisition Corporation (NASDAQ: EFHTU). The firm gave Apexigen a Buy rating with an $8 price target.

Apexigen is “a clinical-stage biopharmaceutical company that is discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immno-oncology products.”

While the words “treatment of cancer” will (and should) grab investors’ attention, you should also be aware of the words “clinical-stage” before you consider buying into this rally for APGN stock. For penny stocks like Apexigen, analyst ratings can give legitimacy to a stock. And that seems to be largely what’s happening right now.

The Vanguard of Cancer Research

That’s not to say the company doesn’t have a compelling story. Few diseases grab the attention of investors as much as cancer. That’s because it’s hard to find a single person who hasn’t been touched by this disease. Many advancements have been made. But a cure is still elusive.

What makes Apexigen distinct is the approach it is taking. The company aims to use the body’s immune system “to combat and eradicate cancer.”

That’s a bold claim. But one the company is backing up. They are trying to create novel immuno-cology drugs to serve one of two functions. Either they will specifically block the immuno-suppression induced by tumors, or they will “actively initiate and augment an immuno response against tumors.”

The company attempts to use a patient’s immune system “to eliminate tumors and prevent their recurrence.”

But the company does not have a product in the market now. However, in November 2022, the company reported positive data from two early-stage clinical trials for sotigalimab, Apexigen’s agonist antibody targeting CD40. According to the National Library of Medicine, CD40 is a co-stimulatory molecule expressed on a range of immune cells and transformed cells in malignant states. Signaling CD40 plays a critical role in modulating adaptive immune responses.

What Is the Reward?

As mentioned above E.F. Hutton recently assigned a price target of $8 to Apexigen’s stock. That would be a gain of over 300% from the current price. This means that the analyst firm is confident that the company will keep delivering positive results in clinical trials for Sotigalimab. And that’s not the only treatment in the company’s pipeline.

However, the sky is the limit when it comes to delivering game-changing cancer treatment. Undoubtedly that has risk-tolerant investors excited about the possibility of getting in on APGN stock at just over $1 per share.

Plus, Apexigen is still, for now, a small-cap stock. Small-cap stocks have a history of leading investors out of bear markets.

What Are the Risks?

Apexigen is not only still in the red but also a pre-revenue company. That means there’s always the chance that the company may need to raise capital.

For penny stock companies, that sometimes means taking actions such as a reverse stock split. When this happens, shareholders receive 1 share at the new price for every X shares they own (typically between 10-25) at the original price.

Keep in mind there’s no sign that Apexigen is planning for this. Typically, this only occurs if the company cannot keep its share price above $1 for at least 10 consecutive trading days. The stock only fell below this threshold in December 2022. And this latest surge pushed APGN stock well above $1. If this holds, investors may have more confidence in holding the stock for the long term.

Recent Quotes

Symbol	Price	Change (%)
GOOG	247.18	+0.61 (0.25%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.